PTHS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pelthos Therapeutics Inc. (PTHS) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators are bearish, the stock lacks positive trading signals, and financial performance shows significant losses despite some YoY improvements. While analysts are optimistic about the company's long-term potential, there is no immediate catalyst or strong sentiment to justify an entry point right now.
The technical indicators for PTHS are bearish. The MACD is below 0 and negatively expanding, the RSI is neutral at 29.317, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 21.752), with resistance levels at R1: 25.954 and R2: 27.252.
and Buy ratings, citing the company's potential in underserved markets with its Zelsuvmi and Xepi drugs. Revenue growth is expected from these launches, and the company has a strong gross margin of 59.56%.
The company reported a significant net loss of -$16.24M in Q3 2025, although this was an improvement YoY. The TRx count for Zelsuvmi missed expectations in Q4 2025, which could indicate slower-than-expected adoption. Technical indicators suggest a bearish trend, and there is no recent news or trading activity to drive momentum.
In Q3 2025, revenue was flat YoY at $7.41M. However, net income improved significantly YoY to -$16.24M (up 858.19%), and EPS increased to -5.3 (up 80.89%). Gross margin remained strong at 59.56%. Despite these improvements, the company is still operating at a loss.
Analysts are optimistic, with multiple Buy ratings and price targets ranging from $50 to $60. They highlight the company's leadership potential in pediatric dermatology and infectious diseases, driven by its Zelsuvmi and Xepi drugs. However, the Q4 TRx count miss introduces some uncertainty about near-term performance.
